Peer Review History
| Original SubmissionMay 22, 2020 |
|---|
|
PONE-D-20-15410 Gamma distribution model of diffusion MRI for the differentiation of primary central nerve system lymphomas and glioblastomas PLOS ONE Dear Dr. Togao, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please do your best to address all of the comments, particularly pay attention to those where references have been missed, as per Reviewer 1's comments. I strongly recommend that you follow each of the suggestions provided by the Reviewers in order to increase the overall readability and interpretation of the results. Please submit your revised manuscript by Aug 24 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Niels Bergsland Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for including your ethics statement: 'This retrospective study was approved by the Institutional Review Board of our hospital (no. 2019-447), and the requirement for informed consent was waived.' (a) Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study. (b) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”). For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research. 3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records were accessed; and c) the source of the medical records analyzed in this work (e.g. hospital, institution or medical center name). [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: ----Summary The manuscript reports the use of the diffusion MRI gamma distribution (GD) model in the differentiation of primary central nervous system lymphomas (PCNSLs) and glioblastomas (GBs). The results indicate that the GD model is advantageous in terms of diagnostic performance when comparing these 2 lesions, namely when 3 specific parameters of this model are used in combination. My overall impression is that the manuscript has quality and it is an interesting an innovative topic, but some aspects should be considered and better analysed. ----Comments to the Author • Abstract: Page 2 - “In this study, we investigate whether whether the gamma distribution (GD) model is useful in this differentiation of PNCSLs. and GBs” – The word “whether” is repeated and the full stop after PNCSLs should be removed. Page 2 - “Receiver operating curve (ROC) analyses were performed to assess diagnostic performance.” – ROC stands for Receiver Operating Characteristic. This should appear as: Receiver Operating Characteristic (ROC) curve. Please check the rest of the document, as this is recurrent. • Introduction: Page 4 – Last paragraph – “The bi-exponential intravoxel incoherent motion (IVIM) model aims to separate the true water diffusion and the capillary perfusion by using multiple b-values [10, 11].” – multiple b-values but specifically multiple low b-values. Please add the word “low” There are only a few articles in this topic, and the way the authors composed parts of the introduction is very similar to the reference number 22 (Shinmoto et al. 2014) and/or 24 (Borlinhas et al. 2019 ) of the document, and sometimes being exactly the same, but not being cited. Example 1 “The IVIM model has an associated uncertainty to the estimated pseudodiffusion, and perfusion fraction, and a possible overparametrization of the model.7 The limitations of the DKI model are related to the unclear biological interpretation of the mean kurtosis parameter, and to the effects of the high b-values that the model requires.” – Reference 24 of the manuscript “The bi-exponential model could be influenced by an uncertainty of the estimated perfusion, since signal measurements at low b-values are susceptible to measurement errors [15-17]. The DKI model is limited by the unclear biological interpretation of the kurtosis parameters [18-20].” – The actual text in the manuscript Example 2 “The GD model allows us to estimate fractions of a tissue type based on the concept that the area fractions for D <1.0 × 10−3 mm2/sec, 1.0 × 10−3 to 3.0 ×10−3 mm2/sec, and D >3.0 ×10−3 mm2/sec are attributed to intracellular, extracellular extravascular, and intravascular spaces, respectively [21].” – The actual text in the manuscript – “ADC values smaller than 1.0 mm2/scan be attributed to small tumor cells with restricted diffusion, and ADC values larger than 3.0 mm2/s can be attributed to perfusion, with ADC values between 1.0 mm2/sand 3.0 mm2/s attributed to water diffusion in the other components.” – Reference 21 of the manuscript – “(…)extracellular fluid (ADCs between 1.0 and 3.0 mm2/s)" – Reference 22 of the manuscript – “Through the PDF of ADC, three different areas under the function’s curve are defined as follows: the fraction of diffusion lower than 1.00 × 10-3 mm2/s is the f1 fraction and it reflects the small cell component; the fraction of diffusion higher than 3.00 × 10-3 mm2/s is the f3 fraction and it reflects the perfusion component; and the fraction of diffusion between 1.00 × 10-3 mm2/s and 3.00 × 10-3 mm2/s is the f2 fraction translating the extracellular component of the tissue.12,13” - Reference 24 of the manuscript In this case, and as you can see, reference 21 is not specific when mentioning the meaning of f2. You have more specific references such as number 22 and 24 of your document. Please add these references. Page 5 - “The GD model allows us to estimate fractions of a tissue type based on the concept that the area fractions for D <1.0 × 10−3 mm2/sec, 1.0 × 10−3 to 3.0 ×10−3 mm2/sec, and D >3.0 ×10−3 mm2/sec are attributed to intracellular, extracellular extravascular, and intravascular spaces, respectively [21]” – This part “1.0 × 10−3 to 3.0 ×10−3 mm2/sec” must appear as “D=1.0 × 10−3 to 3.0 ×10−3 mm2/sec” Page 5 – “The GD model is suitable for realistically interpreting diffusion data in a histological context.” - This sentence is very abrupt. If the reference you are using is the reference 21, Oshio et al. cautiously concluded the following: “(…) histological interpretation of the data appears possible.” In Oshio et al. work, the peripheral zone of the prostate and a prostate cancer were being compared, not different histological types of lesions for example. Your sentence can be misinterpreted. Also, this sentence that you present should be connect to the information included in this paragraph. Page 5 – “The GD model has been used to assess prostate cancers [21-23], breast cancers [24], and renal function [25]. To the best of our knowledge, its application to brain tumours has never been reported. We conducted the present study to determine whether the GD model is useful in the differentiation of PCNSLs and GBs.” – To the best of my knowledge that is true, but the GD model has been applied to brain studies. This is a relatively new application, and consequently, it would be worth mentioning this fact. Here is the a reference that you can use: Grinberg F, Farrher E, Ciobanu L, Geffroy F, Le Bihan D, et al. (2014) Non-Gaussian Diffusion Imaging for Enhanced Contrast of Brain Tissue Affected by Ischemic Stroke. PLoS ONE 9(2): e89225. doi:10.1371/journal.pone.0089225 • Material and Methods - Patients Page 6 - “Multi-b-value DWI” – It would be more adequate to read for example “The use of a DWI protocol with multiple b-values (…)” Page 6 – The difference between the number of PCNSLs and GBs is relevant. Knowing that the PCNSLs are less frequent when compared to the GBs, this information could be added to justify the difference in the groups. If available, the characteristics of the GB, like fraction of necrosis or haemorrhage should be reported. The addition of these characteristics would be enriching the study and could explain some outliers in the results. - ROI placement Page 9 – The legend of this figure 1 repeats the information that it is presented in the text: “The ROIs were also placed on the noncontrast-enhancing T2-hyperintense areas as well as on the contralateral normal-appearing white matter on the image obtained with the b-value of 0 sec/mm2 image.” The reason why and the purpose of placing ROIs on the noncontrast-enhancing T2-hyperintense areas should be stated. - Statistical Analysis Page 9 – “The optimal cutoff point was determined by Youden's method.” – A literature reference should be provided to support the method. Page 10 – “To determine whether the combination of multiple parameters for both the GD model and the IVIM model increases the diagnostic performance, we first performed a stepwise analysis to select appropriate parameters, and then we performed a binomial logistic regression analysis to examine the combinations of the selected parameters.” – Does “appropriate” means with the best diagnostic performances? “Examine” in what way? This should be presented in a clearer way. • Results - Comparisons of the parameters between the PCNSL and GB groups Page 10 - 11 - “Figure 2 illustrates the results of our comparisons of the GD model-derived parameters between the PCNSLs and GBs in the gadolinium-enhancing lesions. The κ was significantly smaller in the PCNSL group (2.26 ± 1.00) than in the GB group (3.62 ± 2.01, p=0.0004). The θ was not significantly different between the groups. The f1 was significantly larger in the PCNSL group (0.542 ± 0.107) than in the GB group (0.348 ± 0.132, p<0.0001). The f2 was significantly smaller in the PCNSL group (0.372 ± 0.098) than in the GB group (0.508 ± 0.127, p<0.0001). The f3 was also significantly smaller in the PCNSL group (0.086 ± 0.043) than in the GB group (0.144 ± 0.062, p<0.0001). The detailed information for the parameters is summarized in Table 1. Figure 3 provides a PCNSL case that showed a ring-like enhancing mass lesion mimicking a GB. This lesion showed a low κ, a large f1, a small f2, and a small f3, suggesting PCNSL. Figure 4 demonstrates a GB case that showed a solid enhancing mass lesion. This lesion showed a small κ, a small f1, moderate f2 and large f3, which are consistent with GB. In the T2-hyperintense areas without contrast enhancement, no significant differences were found between the PCNSL and GB groups for any of the GD model derived parameters.” - This paragraph should be written in a more fluid way so the reader can better understand the ideas that the authors chose to highlight. Page 14 – The results T2-hyperintense areas without contrast enhancement were mentioned but no analysis was made to the NAWM results. If the results were obtained these should be used to support the information shown about the GD model in the manuscript. Page 14 – In the "all data" excel sheet for f parameter you use percentage and here you show a fraction. Please make it uniform to clearly inform the reader. Page 18 – “(…) although the difference was not significantly different from the values for D (p=0.5276).” – This should be rephrased. - Correlations of the model parameters Page 18 – “The f1 had an almost perfect inverse correlation with D (all, r = −0.976, p<0.0001; (…)” – According to figure 6, r = −0.9756, please confirm the information and change where necessary. Page 18 – Considering that the correlation between f2 and D parameters is 0.88657, and it is mentioned because it is high compared to the other correlations, the correlation between f1 and f2 should also be mentioned. The correlation between f1 and f2 is above 0.9155 and the meaning of this result can be of interest to be discussed in the appropriate section of this work. • Discussion - The meaning of f3 and f parameters results and finding should be analysed in the discussion. Why f and f3 parameters are higher in the PCNSL when compared to the GB group of lesions? - Another important result, which should be discussed, is that with the GD model parameters (κ, f1, and f3) it was possible to obtain a higher AUC when compared to ADC’s AUC. Can the author provide a justification or further analysis? Page 20 – “The reason for the slightly higher AUC observed with the ADC could be the effect of perfusion on ADC measurements.” - Can the effect of perfusion on ADC explain the higher AUC observed? If that is the case, in what way can this be explained? Page 21 – “We found the correlations between the GD model-derived and IVIM-derived parameters.” – This sentence is vague or incomplete please consider revising it. Page 21 – “The almost perfect correlation observed between the f1 and D may indicate that these two parameters contain virtually identical information.” – It would be important to mention that it is a negative correlation. Page 21 – “The positive correlation between f2 and D suggests the opposite, and the increased extracellular space like that taken up by microscopic necrosis might result in the higher f2.” – The “opposite” to what? Page 21 – “Although the GD-derived and IVIM-derived parameters provide similar information, the strength of the GD model-derived parameters is that the values are expressed as a fraction or percentage, which allows us to characterize tumors from histological viewpoint.” - “f “ is an IVIM-derived parameter and it is also expressed in percentage or fraction. Page 21 – “The high f2 values in both types of tumor are likely to reflect mostly perifocal vasogenic edema rather than tumor infiltration outside the enhancing lesion” – “high f2 values” relative to what? The sentence would be more specific if it mentioned that it is referring to T2-hyperintense lesions. This idea would benefit from an addition of a literature reference. Page 22 – Another limitation is the fact that only one person performed the ROI placement. The fact that the highest b-value in use was 1000s/mm2, should be better justified since in the brain higher b-values are usually used. - Figures Figure 1. It would be interesting to have the non-contrast-enhancing T2 image where the ROIs were also placed. Figure 5 The y axis title is missing Figure 6 Units should be included, when appropriate. - Tables Table 1 It would be easier to interpret the information shown in the table if p-values were also presented. Table 2 In this table the reader is first exposed to the combination of parameters that were used to estimate diagnostic performances, additionally to the estimation of the diagnostic performances with the individual parameters. Why these specific combinations of parameters were considered? The justification should be clearly stated in the text. In the legend “D, true diffusion coefficient; D*, ç; f, perfusion fraction” the meaning of D* is missing. - Supporting information Units should be added to the “all data” table where appropriate. ----Statement: The topic is interesting but there are some parts of the study which the description should be improved so the reader can better understand it. The major strengths of the article are: the application of a new diffusion model to brain tumours, which as far as I know it has not been done yet; the inclusion of an analysis of combined parameters and the evaluation of its performance; the inclusion of healthy tissue results, but these results were not compared to the results obtain for tumours which is a weakness. Consequently, the relevant weaknesses of the work are: the need for a deeper analysis of the obtained results; there are some methods and procedures that should be better described and justified; the use of b=1000 s/mm2 as the highest b-value is unusual in a brain diffusion studies, and this should be further justified. Note: “Have the authors made all data underlying the findings in their manuscript fully available?” My answer was “no” because I only had access to the summary statistics, and not to the data points behind the statistics. Reviewer #2: This study examined gamma distribution model of diffusion MRI and this model is useful to differentiate malignant lymphoma and glioblastoma. This is well written paper and there are some minor points to revise. In table 1, clarify the statistical significant differences between PCNSL and GB. In figure 4, the k and f2 values at lateral peritumor area (lateral side) are high compared to contrast-enhanced tumor area. Discussion Limitation. The authors evaluate the only one slice of tumor, not whole tumor volume. Add this point in the limitation. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-15410R1 Gamma distribution model of diffusion MRI for the differentiation of primary central nerve system lymphomas and glioblastomas PLOS ONE Dear Dr. Togao, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. There are just a few relatively minor issues to be addressed as pointed out by Reviewer 1. Please submit your revised manuscript by Nov 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Niels Bergsland Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed the topics indicated in the first revision and the manuscript has been significantly improved. Here, the authors can find some small details that still need to be considered. • Results (Page 19, Line 11-12) “..., although the AUC for this combination was not significantly different from that for D (p=0.5276).” "This combination increased the diagnostic performance of f (p=0.0077), although the AUC for this combination was not significantly different from that for D (p=0.5276)." - The language used in the phrases “(…) significantly different from that for (…)”through all the text should be rewritten in a clearer way in order to sound. • Discussion (Page 23, Line 5-7) “The negative correlation between f1 and f2 was likely due to the complementary relationship between these two parameters. Since the f3-values were smaller compared to the f1- and f2-values, the increase in f1 would result in the decrease in f2, and vice versa.” - An explanation for this relation should be put forward taking into account the meaning of the parameters. • “Page 21 “Although the GD-derived and IVIM-derived parameters provide similar information, the strength of the GD model-derived parameters is that the values are expressed as a fraction or percentage, which allows us to characterize tumours from histological viewpoint.” - “f “ is an IVIM-derived parameter and it is also expressed in percentage or fraction. Response: Yes, as you pointed out, the IVIM-f is expressed in percentage or fraction. But the IVIM method cannot express the fractions or percentage of intracellular and extracellular-extravascular spaces. Therefore, we think IVIM is not a perfect method to characterize tumours from histological viewpoint.” - In the way this sentence is presented, the reader may misunderstand the information that you are providing. You are stating that one strong point of the GD model parameters, when compared to IVIM parameters, is to be presented in percentage or fraction and that this is the reason why it allows the characterization of tumours. f is also expressed as fraction or percentage and it shows problems in this task. In the way that the sentence is constructed the reader may think that only GD parameters are expressed in fraction or percentage. Also, it is important to refer in what way can this characteristic contribute to the characterization of tumours' histology. • Figure 1 - The name of the lesions should be included. Also, the lesions/ROIs in the images should be identified for example with numbers or letters, and that should be referenced and related in the legend of the figure. Reviewer #2: The paper is revised as reviewer's comments and it is acceptable in this version. This is very useful information for brain tumor imaging. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Yoshiyuki Watanabe [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Gamma distribution model of diffusion MRI for the differentiation of primary central nerve system lymphomas and glioblastomas PONE-D-20-15410R2 Dear Dr. Togao, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Niels Bergsland Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors addressed the topics indicated in the previous review. The article provides an understanding of an important topic by applying a method that can bring more in-depth knowledge to this field of study. Note that in Figure 1, the numbers that identify the ROIs are covering the relevant structures, which can raise doubts among readers. Please consider a solution, as for example the use of different colours to differentiate the ROIs instead, or a different positioning of the numbers. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Filipa Borlinhas |
| Formally Accepted |
|
PONE-D-20-15410R2 Gamma distribution model of diffusion MRI for the differentiation of primary central nerve system lymphomas and glioblastomas Dear Dr. Togao: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Niels Bergsland Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .